A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor Administered with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumours
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
May 1, 2016
End Date
June 18, 2018
Administered By
Duke Cancer Institute
Awarded By
Eli Lilly and Company
Start Date
May 1, 2016
End Date
June 18, 2018